Status:
COMPLETED
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborating Sponsors:
Kite, A Gilead Company
Conditions:
Diffuse Large B Cell Lymphoma
Transformed Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosed with diffuse large b-cell lymphoma, primary mediastinal b-cell lymphoma or transformed follicular lymphoma
- Scheduled to receive commercial axi-cel at Moffitt Cancer Center
- Able to speak and read standard english
- Have no documented or observable psychiatric or neurological diagnoses that interfere with study participation (e.g., schizophrenia)
- Have no history of traumatic brain injury, stroke, or dementia
- Able to provide informed consent
Exclusion
Key Trial Info
Start Date :
March 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04319237
Start Date
March 10 2020
End Date
July 31 2023
Last Update
December 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Moffitt Cancer Center
Tampa, Florida, United States, 33612